![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.480, 2005-01, pp. : 15-15
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Adjuvant regimen with docetaxel best bet in operable breast cancer
Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Liubao Peng
PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Docetaxel regimen improves survival in early breast cancer
Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)